MSLE · Satellos Bioscience Inc.
Market Cap
$136.63M
Shares
21.22M
Volume · Oct 20
13.55K
Avg daily vol (3M)
45.39K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.00
Open$6.39
Day$6.39–7.03
52W close$5.59–13.01
Avg vol 30d57K
Short int106K · 0.5% float · 1.6d
Short vol63%
Last earningsJul 8, 2026
DataJan 2020–Oct 2026
Up next
call held Jul 8, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.5%
Latest settlement · 1.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bearish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−18%
below
Price vs 50-day avg
−21%
below
RSI (14)
37
neutral
MACD trend
Negative
52-week position
19%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−21%
trailing
6-month return
−4%
trailing
YTD return
+19%
this year
Relative strength
−12%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $8 — 50d above 200d
Institutional flow
Distributing
-16% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.50% of float · ▲ +28.2% MoM · 1.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
26 holders — 13F breadth
Squeeze score
44
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
83%
annualized · 1-yr
Max drawdown
−57%
past year
ATR
8.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−18%
Bearish
Price vs 50-day avg
−21%
Bearish
RSI (14)
37
Neutral
MACD trend
Negative
Bearish
52-week position
19%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $9 › 200d $8 — 50d above 200d
Institutional flow
Distributing
-16% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.50% of float · ▲ +28.2% MoM · 1.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
26 holders — 13F breadth
Price context
position in its 52-week range
Range low $6
Now $7 · 19%
Range high $13
vs 200-day avg -18%
vs 50-day avg -21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MSLE
this stock
Satellos Bioscience Inc.
|
$136.63M | — | — | — | 0.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +13.5% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +4.6% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MSLE | -0.6% | -21.1% | -3.7% | -17.7% | +19.1% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | +0.6% | -20.5% | -11.8% | -18.5% | +6.3% |